葛兰素史克Glaxosmithkline（GSK）2025年企业治理报告「LSE」（英文版）（63页）.pdf

1、CorporategovernanceIn this sectionThe Board and Executive Committee109Chairs governance statement115Corporate governance architecture118Board activities121Board committee reports129Remuneration report140Directors report169GSK Annual Report 2025108Sir Jonathan Symonds,CBENon-Executive Chair Age:67Nat

2、ionality:BritishAppointed:1 September 2019Skills and experienceJon has extensive international financial,life sciences and governance experience.Jon served as a Non-Executive Director of Genomics England from October 2013 to October 2025.From April 2014 until February 2020,he was an Independent Non-

3、Executive Director of HSBC Holdings plc where he also served as Chairman of the Group Audit Committee and as Deputy Group Chairman from August 2018.Jon was previously Chairman of HSBC Bank plc,Chief Financial Officer of Novartis AG,Partner and Managing Director of Goldman Sachs,ChiefFinancial Office

4、r of AstraZeneca plc,and a Partner at KPMG.He was also a Senior Advisor to Chatham House.Jon is a Fellow of the Institute of Chartered Accountants in England and Wales,an Honorary Fellow of the Oxford School of Pharmacology,and an Honorary Fellow of the Academy of Medical Sciences.External appointme

5、nts Non-Executive Chair,Energy Aspects;Member,European Round Table for Industry;Member,Investor&Issuer Forum(I&IF)Steering Committee.Luke MielsChief Executive OfficerAge:51Nationality:AustralianAppointed:1 January 2026Skills and experienceLuke became CEO and joined the Board on 1 January 2026,follow

6、ing his appointment as CEO designate in September 2025.Luke joined GSK in 2017 as Chief Commercial Officer,responsible for our commercial portfolio ofmedicines and vaccines.He previously worked for AstraZeneca as Executive Vice President oftheir European business and,prior to that,was Executive Vice